Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
Additional Business Intelligence Offerings
Lab Industry Advisor Subscriptions Include
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
Exosome Prostate Cancer Test Does Well in Clinical Validation Study
By Ron Shinkman, Editor, Laboratory Industry Report Massachusetts-based Exosome Diagnostics has released data from a clinical validation study suggesting its liquid biopsy test for prostate cancer patients could more accurately predict the presence of the disease...
Sequencing to Target Pancreatic Cancer Tx ‘Challenging’ in Real World
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Real-world application of sequencing for targeting pancreatic cancer treatment remains challenging, according to a study published in Clinical Cancer Research and presented at the American...
FDA Approves Roche’s KRAS Mutation Test
By Stephanie Murg, Managing Director, G2 Intelligence Roche's portfolio of companion diagnostics now includes a test that can help clinicians to tailor treatment for patients with metastatic colorectal cancer. The U.S. Food and Drug Administration has approved the...
Technology Connects Lab-Discarded Specimens with Researchers; Provides Labs New Revenue
By Kelly A. Briganti, Editorial Director, G2 Intelligence Technology is making use of hospital and laboratory specimens that would otherwise be discarded by connecting those specimen sources with biomedical researchers. iSpecimen (Lexington, Mass.), founded in...